Participants report feeling empowered by comprehensive screening
TUESDAY, Sept. 20, 2022 (HealthDay News) — Psoriatic arthritis (PsA) screening is acceptable to patients with psoriasis whether they are diagnosed with PsA or not, according to a research letter published online Aug. 17 in the British Journal of Dermatology.
Christine A. Silverthorne, from the University of the West of England in Bristol, and colleagues sought to understand the experience of screening from the perspective of 21 participants with psoriasis. Screening included an examination of skin, joints, hands, feet, scalp, physical tests (e.g., touching toes), height and weight measurement, blood tests, X-rays, magnetic resonance imaging scans, and questionnaires.
The researchers identified three main themes. First, screening was perceived as well-conducted and, overall, a positive and reassuring experience. Participants reported appreciating the thoroughness of the examination and the time to talk with specialists. Secondly, screening provided participants a sense of control over their health. Among those screening positive for PsA, they valued the help they were given in treating their condition, while those screening negative gained an awareness of symptoms for which to watch out. Lastly, participants suggested improvements to the screening process, including using case studies, signposting to support groups, and providing information. They also indicated barriers to screening, which included location, parking, and time of appointments.
“This qualitative study indicates that screening is acceptable and a potentially valuable method to increase the early detection of PsA in patients with psoriasis and improve their clinical outcomes,” the authors write.
2005 to 2023 Saw More U.S. Women Never Screened for Cervical Cancer
Machine Learning Model IDs Heart Failure With Reduced Ejection Fraction Using Routine Lab Indicators
Addition of CAC to PREVENT-ASCVD Equations May Improve Predictive Utility in Certain Patients
Drug Retention in Spondyloarthritis Varies With Socioeconomic Status
Timing of JAK Initiation, Shingles Vaccine Administration Can Affect Outcomes in RA
Bimekizumab Well Tolerated, Efficacious Over Three Years in Axial Spondyloarthritis
Longer Persistence Seen With Upadacitinib Versus TNFi in Rheumatoid Arthritis
Achieving Low Serum Urate Levels Can Cut Risk for Cardiovascular Events in Gout